Eastern Hill Academic Centre - Research Publications

Permanent URI for this collection

http://hdl.handle.net/11343/197486

Filters

2013 1
Reset filters

Settings
Statistics
Citations
Author: Dickinson, Michael × Author: CHEAH, CHAN YOON × Author: Herbert, Kirsten × Type: Journal Article ×

Search Results

Now showing 1 - 1 of 1
  • Item
    Thumbnail Image
    Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy
    Cheah, CY ; Hofman, MS ; Dickinson, M ; Wirth, A ; Westerman, D ; Harrison, SJ ; Burbury, K ; Wolf, M ; Januszewicz, H ; Herbert, K ; Prince, HM ; Carney, DA ; Ritchie, DS ; Hicks, RJ ; Seymour, JF (NATURE PUBLISHING GROUP, 2013-07-23)
    BACKGROUND: The usefulness of positron emission tomography with computed tomography (PET-CT) in the surveillance of patients with diffuse large B-cell lymphoma (DLBCL) in complete metabolic remission after primary therapy is not well studied. METHODS: We performed a retrospective review of our database between 2002 and 2009 for patients with de novo DLBCL who underwent surveillance PET-CT after achieving complete metabolic response (CMR) following primary therapy. RESULTS: Four-hundred and fifty scans were performed in 116 patients, with a median follow-up of 53 (range 8-133) months from completion of therapy. Thirteen patients (11%) relapsed: seven were suspected clinically and six were subclinical (all within first 18 months). The positive predictive value in patients with international prognostic index (IPI) <3 was 56% compared with 80% in patients with IPI ≥3. Including indeterminate scans, PET-CT retained high sensitivity 95% and specificity 97% for relapse. CONCLUSION: Positron emission tomography with computed tomography is not useful in patients for the majority of patients with diffuse large B-cell lymphoma in CMR after primary therapy, with the possible exception of patients with baseline IPI ≥3 in the 18 months following completion of primary therapy. This issue could be addressed by a prospective clinical trial.